Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02804750 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

A Phase 2 study of Cushing's Syndrome, sponsored by Corcept Therapeutics.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
20
Study locations

NCT02804750 is a Phase 2 study of Cushing's Syndrome that has completed, run by Corcept Therapeutics. The registered enrollment target is 35 participants, below the 931-participant average among 4 other Cushing's Syndrome trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02804750, a Phase 2 study of Cushing's Syndrome, has completed, sponsored by Corcept Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
20
Study locations

Study Summary

Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, were not eligible for enrollment in this study. The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study was conducted in the United States and in Europe.

Conditions Studied

Cushing's Syndrome

Interventions

  • DRUG CORT125134

Study Locations (20)

Other

  • - Budapest
  • - Pécs
  • - Cuneo
  • - Messina
  • - Milan
  • - Naples
  • - Orbassano
  • - Roma

Florida

  • - Fort Lauderdale
  • - Miami

California

  • - Laguna Hills

Colorado

  • - Aurora

Indiana

  • - Indianapolis

Kentucky

  • - Covington

Minnesota

  • - Rochester

Missouri

  • - St Louis

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2016-06
Est. Completion 2018-09
Phase Phase 2

Sponsor

Corcept Therapeutics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02804750

The ClinicalTrials.gov registry entry for NCT02804750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 931-participant average among 4 other Cushing's Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cushing's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which CORT125134 is the first listed.

NCT02804750 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, California.

Frequently Asked Questions

What is clinical trial NCT02804750 about?

NCT02804750 is a clinical study titled "Study to Evaluate CORT125134 in Participants With Cushing's Syndrome". Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the ad...

What is the current status of trial NCT02804750?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-06. Estimated completion is 2018-09.

What conditions does trial NCT02804750 study?

This clinical trial studies the following conditions: Cushing's Syndrome.

What interventions are being tested in trial NCT02804750?

The interventions under investigation include: CORT125134 (DRUG).

Who is sponsoring clinical trial NCT02804750?

This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02804750 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cushing's Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cushing's Syndrome

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.